多奈单抗治疗后淀粉样蛋白水平与早期症状性阿尔茨海默病临床结局的相关性
本研究为TRAILBLAZER-ALZ 2随机对照试验的事后探索性分析,纳入1582例早期症状性AD患者,按治疗后最低淀粉样蛋白水平十分位分组。结果显示,治疗后淀粉样蛋白水平越低,iADRS(R²=0.73)和CDR-SB(R²=0.87)评估的临床进展越慢,且p-tau217、p-tau181和GFAP下降越明显,但NfL无相关性。
要点
- 多奈单抗组治疗后淀粉样蛋白水平低于安慰剂组。
- 治疗后淀粉样蛋白水平越低,临床进展越慢(iADRS R²=0.73,CDR-SB R²=0.87)。
- 治疗后淀粉样蛋白水平与p-tau217、p-tau181、GFAP下降相关,与NfL无关。
核心结论
- 治疗后淀粉样斑块水平与临床获益相关,支持淀粉样斑块清除是多奈单抗的作用机制,且淀粉样斑块水平可作为靶向淀粉样蛋白治疗的潜在替代生物标志物。
研究设计与样本
- TRAILBLAZER-ALZ 2随机、安慰剂对照3期试验的事后探索性分析,2020年6月至2023年4月在8个国家277个医学研究中心/医院进行。
- 共评估8240例60至85岁早期症状性AD且PET显示淀粉样蛋白和tau病理的参与者,排除6504例后纳入1582例(多奈单抗组766例,安慰剂组816例)。
- 参与者按1:1随机接受多奈单抗(前3剂700 mg,之后1400 mg)或安慰剂静脉输注,每4周一次,最长72周,结局评估至76周。
主要发现
- 多奈单抗组治疗后淀粉样蛋白值低于安慰剂组。
- 在全试验人群中,治疗后淀粉样蛋白水平越低,iADRS评分进展越慢(R²=0.73 [95% CI, 0.37-0.97]),CDR-SB评分进展越慢(R²=0.87 [95% CI, 0.70-0.97])。
- 治疗后淀粉样蛋白水平越低,p-tau217下降越明显(R²=0.86 [95% CI, 0.73-0.97]),p-tau181下降越明显(R²=0.88 [95% CI, 0.77-0.97]),GFAP下降越明显(R²=0.87 [95% CI, 0.76-0.97])。
- 治疗后淀粉样蛋白值与NfL无相关性(R²=0.03 [95% CI, 0.00-0.54])。
临床怎么用
- 治疗后淀粉样蛋白水平可作为评估多奈单抗疗效的潜在替代生物标志物,辅助临床决策。
- 临床可结合iADRS、CDR-SB及血浆p-tau217、p-tau181、GFAP动态监测治疗反应。
局限性
- 本研究为事后探索性分析,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accumulation of amyloid plaque drives pathogenesis of Alzheimer disease (AD). Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. OBJECTIVE: To assess the correlation of posttreatment amyloid levels with clinical outcomes and biomarkers in AD. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc exploratory analysis from the randomized, placebo-controlled phase 3 trial, TRAILBLAZER-ALZ 2, conducted June 2020 through April 2023 at 277 medical research centers/hospitals in 8 countries. A total of 8240 participants aged 60 to 85 years with early symptomatic AD with amyloid and tau pathology based on positron emission tomography (PET) imaging were assessed for eligibility. Of these, 6504 participants were excluded predominantly due to inadequate amyloid or tau pathology. The current analysis included 1582 participants (766 in the donanemab group and 816 in the placebo group) with baseline and at least 1 posttreatment assessment. Data analysis took place from July 2024 to March 2025. INTERVENTIONS: Participants were randomized 1:1 to receive donanemab (700 mg for the first 3 doses and 1400 mg thereafter) or placebo intravenously every 4 weeks for up to 72 weeks, with outcomes assessed through 76 weeks. MAIN OUTCOMES AND MEASURES: Participants were categorized into 1 of 10 groups (deciles) based on their lowest amyloid value observed posttreatment. Clinical progression was assessed via changes in integrated Alzheimer's Disease Rating Scale (iADRS) and Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores. Plasma biomarkers measured included phosphorylated tau 217 (p-tau217), p-tau181, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). Correlations between the median amyloid level in each decile were assessed with 76-week least-squares mean changes in each outcome and biomarker. RESULTS: Analyses included 1582 participants, including 766 treated with donanemab and 816 with placebo. The mean (SD) age was 72.9 (6.2) years, and 900 participants (56.9%) were female. Participants who received donanemab had lower posttreatment amyloid values than those in the placebo group. Across the trial population, lower posttreatment amyloid levels were correlated with slower clinical progression as measured by iADRS score (R2, 0.73 [95% CI, 0.37-0.97]) and CDR-SB score (R2, 0.87 [95% CI, 0.70-0.97]) and with decreases in p-tau217 (R2, 0.86 [95% CI, 0.73-0.97]), p-tau181 (R2, 0.88 [95% CI, 0.77-0.97]), and GFAP (R2, 0.87 [95% CI, 0.76-0.97]). There was no correlation between posttreatment amyloid value and NfL (R2, 0.03 [95% CI, 0.00-0.54]). CONCLUSIONS AND RELEVANCE: The findings in this secondary analysis of a randomized clinical trial demonstrating a correlation between posttreatment amyloid plaque level and clinical benefit support amyloid plaque removal as the mechanism of action for donanemab treatment and the level of amyloid plaque as a potential surrogate biomarker in amyloid-targeting therapies. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04437511.
引用
- Lu M, Kim MJ, Collins EC, et al. Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 41082199. doi:10.1001/jamaneurol.2025.3869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。